Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Infinity Pharmaceuticals Earnings Perspective: Return On Capital Employed

Infinity Pharmaceuticals (NASDAQ:INFI) brought in sales totaling $451.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 8.76%, resulting in a loss of $11.65 million.

Benzinga

Looking Into HTG Molecular Diagnostics's Return On Capital Employed

HTG Molecular Diagnostics (NASDAQ:HTGM) brought in sales totaling $2.88 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 15.6%, resulting in a loss of $5.19 million.

Benzinga

Looking Into BioCardia's Return On Capital Employed

Benzinga Pro data, BioCardia (NASDAQ:BCDA) reported Q4 sales of $79.00 thousand. Earnings fell to a loss of $3.46 million, resulting in a 27.9% decrease from last quarter.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Cormedix's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, Cormedix's (NASDAQ:CRMD) reported sales totaled $56.40 thousand. Despite a 9.08% increase in earnings, the company posted a loss of $7.79 million.

Benzinga

Looking Into Sarcos Technology's Return On Capital Employed

According to Benzinga Pro data, during Q4, Sarcos Technology (NASDAQ:STRC) posted sales of $1.00 million. Earnings were up 7.9%, but Sarcos Technology still reported an overall loss of $34.06 million.

Benzinga

Nabriva Therapeutics's Return On Capital Employed Overview

Nabriva Therapeutics (NASDAQ:NBRV) brought in sales totaling $9.26 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.63%, resulting in a loss of $13.06 million.

Benzinga

Looking Into Sera Prognostics's Return On Capital Employed

Benzinga Pro data, Sera Prognostics (NASDAQ:SERA) reported Q4 sales of $26.00 thousand. Earnings fell to a loss of $12.48 million, resulting in a 26.63% decrease from last quarter.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Humacyte's Return On Capital Employed Insights

Pulled from Benzinga Pro data, Humacyte (NASDAQ:HUMA) posted Q4 earnings of $42.59 million, an increase from Q3 of 234.92%. Sales dropped to $177.00 thousand, a 26.56% decrease between quarters.

Benzinga

Academy Sports Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data Academy Sports (NASDAQ:ASO) posted a 12.11% decrease in earnings from Q3. Sales, however, increased by 13.5% over the previous quarter to $1.81 billion.

Benzinga

Crown ElectroKinetics: Q3 Earnings Insights

Crown ElectroKinetics (NASDAQ:CRKN) reported its Q3 earnings results on Wednesday, March 30, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

Kala Pharmaceuticals's Return On Capital Employed Insights

Benzinga Pro data, Kala Pharmaceuticals (NASDAQ:KALA) reported Q4 sales of $1.86 million. Earnings fell to a loss of $47.57 million, resulting in a 69.12% decrease from last quarter.

Benzinga

Mid-Morning Market Update: Markets Mixed; US GDP Grows 6.9% In Q4

U.S. stocks traded mixed this morning following the release of GDP data.

Benzinga

Berkshire Grey Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q4, Berkshire Grey's (NASDAQ:BGRY) reported sales totaled $23.59 million. Despite a 10.01% increase in earnings, the company posted a loss of $36.45 million.

Benzinga

Looking Into SCYNEXIS's Return On Capital Employed

SCYNEXIS (NASDAQ:SCYX) brought in sales totaling $597.00 thousand during Q4 according to data provided by Benzinga Pro. However, earnings decreased 4733.55%, resulting in a loss of $29.24 million.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking Into Cadiz's Return On Capital Employed

According to Benzinga Pro data, during Q4, Cadiz (NASDAQ:CDZI) posted sales of $142.00 thousand. Earnings were up 24.68%, but Cadiz still reported an overall loss of $5.90 million.

Benzinga

Verint Systems Earnings Perspective: Return On Capital Employed

Benzinga Pro data, Verint Systems (NASDAQ:VRNT) reported Q4 sales of $236.18 million. Earnings fell to a loss of $4.26 million, resulting in a 131.55% decrease from last quarter.

Benzinga

Lululemon Athletica's Return on Invested Capital Overview

According to Benzinga Pro, during Q4, Lululemon Athletica (NASDAQ:LULU) earned $434.50 million, a 131.38% increase from the preceding quarter. Lululemon Athletica also posted a total of $2.13 billion in sales, a 46.83% increase since Q3.

Benzinga

Conn's's Return on Invested Capital Insights

Pulled from Benzinga Pro data, Conn's (NASDAQ:CONN) posted Q4 earnings of $7.56 million, an increase from Q3 of 58.53%. Sales dropped to $402.49 million, a 0.73% decrease between quarters.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Looking Into Cal-Maine Foods's Return On Capital Employed

According to Benzinga Pro, during Q3, Cal-Maine Foods (NASDAQ:CALM) earned $39.45 million, a 3345.76% increase from the preceding quarter. Cal-Maine Foods also posted a total of $477.49 million in sales, a 22.15% increase since Q2.

Benzinga

Department Of Defense Delays Cloud Computing Contract: What You Need To Know

The Department of Defense has reportedly delayed the joint cloud computing contract decision.

Benzinga

Benzinga's Daily Brief On Trending Tickers For March 30, 2022: Robinhood, Chewy, Tilray And More

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

Benzinga

atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results

atai Life Sciences N.V. (NASDAQ:ATAI) has announced its financial results for the fourth quarter and full year ended December 31, 2021. 2021 Financial Results Highlights included: Positive Phase 2b data with COMP360 from a ground-breaking treatment-resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive impairment…

Benzinga

South Korean Chipmaker Weighs Arm Takeover Options

South Korean chipmaker SK Hynix Inc (OTC:HXSCL) CEO admitted to weighing a consortium to acquire British semiconductor company Arm Ltd, Reuters reports citing Yonhap news agency. “I don’t believe Arm is a company that could be bought by one company,” SK Hynix Vice-Chair and co-CEO Park Jung-ho admitted, FX Empire reports. SoftBank Group Corp (OTC: SFTBY) (OTC: SFTBF) looked…

Benzinga

Tilray To Report Q3 Financial Highlights On Heels Of Deal With HEXO

Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) has announced that it will release financial results for its third-quarter fiscal 2022 ended February 28, 2022, before financial markets open on April 6, 2022.

Benzinga

Sportradar Tops Q4 Backed By Every Segment; Watch For Upcoming CEO Interview

Sportradar Group AG (NASDAQ:SRAD) reported fourth-quarter revenue growth of 41% year-on-year to €152.4 million ($172.2 million), beating the consensus of $156 million. Segments: U.S. revenue increased by 92% Y/Y to €23.2 million ($26.2 million) due to sales of U.S. Betting services. RoW Betting segment revenue rose by 30% Y/Y to €82.2 million due to…

1 … 758 759 760 761

People

John Sherman

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

UEFA Champions League

Department of Defense

Read news from The Economist, FT, and more,
with one subscription

Places

United States

367,292 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.